Targeting TGF-β for treatment of osteogenesis imperfecta
I-Wen Song, Sandesh Cs Nagamani, Dianne Nguyen, Ingo Grafe, Vernon Reid Sutton, Francis H Gannon, Elda Munivez, Ming-Ming Jiang, Alyssa Tran, Maegen Wallace, Paul Esposito, Salma Musaad, Elizabeth Strudthoff, Sharon McGuire, Michele Thornton, Vinitha Shenava, Scott Rosenfeld, Shixia Huang, Roman Shypailo, Eric Orwoll, Brendan Lee, I-Wen Song, Sandesh Cs Nagamani, Dianne Nguyen, Ingo Grafe, Vernon Reid Sutton, Francis H Gannon, Elda Munivez, Ming-Ming Jiang, Alyssa Tran, Maegen Wallace, Paul Esposito, Salma Musaad, Elizabeth Strudthoff, Sharon McGuire, Michele Thornton, Vinitha Shenava, Scott Rosenfeld, Shixia Huang, Roman Shypailo, Eric Orwoll, Brendan Lee
Abstract
BACKGROUNDCurrently, there is no disease-specific therapy for osteogenesis imperfecta (OI). Preclinical studies demonstrate that excessive TGF-β signaling is a pathogenic mechanism in OI. Here, we evaluated TGF-β signaling in children with OI and conducted a phase I clinical trial of TGF-β inhibition in adults with OI.METHODSHistology and RNA-Seq were performed on bones obtained from children. Gene Ontology (GO) enrichment assay, gene set enrichment analysis (GSEA), and Ingenuity Pathway Analysis (IPA) were used to identify dysregulated pathways. Reverse-phase protein array, Western blot, and IHC were performed to evaluate protein expression. A phase I study of fresolimumab, a TGF-β neutralizing antibody, was conducted in 8 adults with OI. Safety and effects on bone remodeling markers and lumbar spine areal bone mineral density (LS aBMD) were assessed.RESULTSOI bone demonstrated woven structure, increased osteocytes, high turnover, and reduced maturation. SMAD phosphorylation was the most significantly upregulated GO molecular event. GSEA identified the TGF-β pathway as the top activated signaling pathway, and IPA showed that TGF-β1 was the most significant activated upstream regulator mediating the global changes identified in OI bone. Treatment with fresolimumab was well-tolerated and associated with increases in LS aBMD in participants with OI type IV, whereas participants with OI type III and VIII had unchanged or decreased LS aBMD.CONCLUSIONIncreased TGF-β signaling is a driver pathogenic mechanism in OI. Anti-TGF-β therapy could be a potential disease-specific therapy, with dose-dependent effects on bone mass and turnover.TRIAL REGISTRATIONClinicalTrials.gov NCT03064074.FUNDINGBrittle Bone Disorders Consortium (U54AR068069), Clinical Translational Core of Baylor College of Medicine Intellectual and Developmental Disabilities Research Center (P50HD103555) from National Institute of Child Health and Human Development, USDA/ARS (cooperative agreement 58-6250-6-001), and Sanofi Genzyme.
Keywords: Bone disease; Clinical Trials; Drug therapy; Therapeutics.
Figures
References
- Marini JC, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. doi: 10.1038/nrdp.2017.52.
- Marom R, et al. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J Med Genet C Semin Med Genet. 2016;172(4):367–383. doi: 10.1002/ajmg.c.31532.
- Patel RM, et al. A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers. Clin Genet. 2015;87(2):133–140. doi: 10.1111/cge.12409.
- Rossi V, et al. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr. 2019;31(6):708–715. doi: 10.1097/MOP.0000000000000813.
- Tam A, et al. A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clin Genet. 2018;94(6):502–511. doi: 10.1111/cge.13440.
- Adami S, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18(1):126–130. doi: 10.1359/jbmr.2003.18.1.126.
- Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev. 2010;86(11):743–746. doi: 10.1016/j.earlhumdev.2010.08.002.
- Bishop N, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1424–1432. doi: 10.1016/S0140-6736(13)61091-0.
- Chevrel G, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21(2):300–306.
- DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21(1):132–140.
- Gatti D, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005;20(5):758–763.
- Gatti D, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448–452. doi: 10.1007/s00223-013-9770-2.
- Glorieux FH, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947–952. doi: 10.1056/NEJM199810013391402.
- Rauch F, et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24(7):1282–1289. doi: 10.1359/jbmr.090213.
- Rauch F, et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18(4):610–614. doi: 10.1359/jbmr.2003.18.4.610.
- Orwoll ES, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491–498. doi: 10.1172/JCI71101.
- Hoyer-Kuhn H, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta — a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24–32.
- Bains JS, et al. A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. JBMR Plus. 2019;3(5):e10118. doi: 10.1002/jbm4.10118.
- Anissipour AK, et al. Behavior of scoliosis during growth in children with osteogenesis imperfecta. J Bone Joint Surg Am. 2014;96(3):237–243. doi: 10.2106/JBJS.L.01596.
- Rauch F, et al. Intracortical remodeling during human bone development — a histomorphometric study. Bone. 2007;40(2):274–280. doi: 10.1016/j.bone.2006.09.012.
- Dwan K, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;10(10):CD005088.
- Dwan K, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10(7):CD005088.
- Shi CG, et al. Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther. 2016;23(3):e894–e904. doi: 10.1097/MJT.0000000000000236.
- Lim J, et al. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone. 2017;102:40–49. doi: 10.1016/j.bone.2017.02.004.
- Grafe I, et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20(6):670–675. doi: 10.1038/nm.3544.
- Nijhuis WH, et al. Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management. J Child Orthop. 2019;13(1):1–11. doi: 10.1302/1863-2548.13.180190.
- Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi: 10.1073/pnas.0506580102.
- Hannan FM, et al. Genetic approaches to metabolic bone diseases. Br J Clin Pharmacol. 2019;85(6):1147–1160. doi: 10.1111/bcp.13803.
- Rachner TD, et al. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276–1287. doi: 10.1016/S0140-6736(10)62349-5.
- Tauer JT, et al. Effect of anti-TGF-β treatment in a mouse model of severe osteogenesis imperfecta. J Bone Miner Res. 2019;34(2):207–214. doi: 10.1002/jbmr.3617.
- Greene B, et al. Inhibition of TGF-β increases bone volume and strengthin a mouse model of osteogenesis imperfecta. JBMR Plus. 2021;5(9):e10530.
- Kaupp S, et al. Combination therapy in the Col1a2(G610C) mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGFbeta signaling on trabecular bone but not on cortical bone. Bone. 2020;131:115084. doi: 10.1016/j.bone.2019.115084.
- Langdahl B, et al. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016;8(6):225–235. doi: 10.1177/1759720X16670154.
- Morris JC, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353. doi: 10.1371/journal.pone.0090353.
- Vincenti F, et al. A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. Kidney Int Rep. 2017;2(5):800–810. doi: 10.1016/j.ekir.2017.03.011.
- Rice LM, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125(7):2795–2807. doi: 10.1172/JCI77958.
- Formenti SC, et al. Focal irradiation and systemic TGFβ blockade in metastatic breast cancer. Clin Cancer Res. 2018;24(11):2493–2504. doi: 10.1158/1078-0432.CCR-17-3322.
- Strauss J, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020;8(2):e001395. doi: 10.1136/jitc-2020-001395.
- Tao JJ, et al. First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. Clin Cancer Res. 2019;25(18):5458–5465. doi: 10.1158/1078-0432.CCR-19-1065.
- Glorieux FH, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32(7):1496–1504. doi: 10.1002/jbmr.3143.
- Eric T, et al. Proceedings of the 2020 Rare Bone Disease Working Group. JBMR Plus. 2021;5(s1):e10455
- Martinez-Hackert E, et al. Receptor binding competition: A paradigm for regulating TGF-β family action. Cytokine Growth Factor Rev. 2021;57:39–54. doi: 10.1016/j.cytogfr.2020.09.003.
- Chou CH, et al. Direct assessment of articular cartilage and underlying subchondral bone reveals a progressive gene expression change in human osteoarthritic knees. Osteoarthritis Cartilage. 2013;21(3):450–461. doi: 10.1016/j.joca.2012.11.016.
- Bu W, et al. Mammary precancerous stem and non-stem cells evolve into cancers of distinct subtypes. Cancer Res. 2019;79(1):61–71. doi: 10.1158/0008-5472.CAN-18-1087.
Source: PubMed